All articles tagged with #cardiometabolic benefits
A study from Harvard T.H. Chan School of Public Health found that nearly one-third of individuals adhering to a healthy diet did not lose weight but still experienced significant improvements in cardiometabolic health markers, highlighting that health benefits can occur independently of weight loss.
A randomized controlled trial involving identical twins found that a healthy vegan diet resulted in significant improvements in LDL cholesterol, fasting insulin levels, and weight loss compared to a healthy omnivore diet. After 8 weeks, the vegan diet group showed a mean decrease of 13.9 mg/dL in LDL-C, a mean decrease of 2.9 μIU/mL in fasting insulin, and a 1.9 kg decrease in body weight. The study suggests that plant-based diets may be recommended by clinicians to reduce cardiometabolic risk factors and align with environmental benefits. However, the study's limitations include a small sample size and a short duration of intervention.
Pemvidutide, an investigational dual agonist of glucagon-like peptide 1 (GLP-1) and glucagon, has shown significant weight loss and cardiometabolic benefits in a phase 2 trial. The drug is part of a growing group of incretin-based weight-loss drugs being developed, offering additional benefits beyond glucose control. Pemvidutide is being studied for the treatment of obesity and nonalcoholic steatohepatitis (NASH), while other drugs like tirzepatide and retatrutide are being explored for type 2 diabetes and fatty liver disease. The trial results showed substantial weight loss, reductions in cholesterol and triglyceride levels, and improvements in blood pressure without affecting glucose homeostasis. Gastrointestinal adverse events were common, but efforts will be made to reduce them in future trials. The full data for the trial will be announced later this year.